Population pharmacokinetics and exposure-response relationship of trastuzumab and bevacizumab in early-stage breast cancer.
Adult
Aged
Antineoplastic Agents, Immunological
/ pharmacokinetics
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Area Under Curve
Bevacizumab
/ pharmacokinetics
Breast Neoplasms
/ drug therapy
Docetaxel
/ therapeutic use
Drug Interactions
Female
Half-Life
Humans
Middle Aged
Models, Biological
Neoplasm Staging
Receptor, ErbB-2
/ genetics
Trastuzumab
/ pharmacokinetics
Bevacizumab
Breast cancer
Monoclonal antibodies
Population pharmacokinetics
Trastuzumab
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
20
08
2020
accepted:
21
06
2021
pubmed:
11
7
2021
medline:
4
2
2022
entrez:
10
7
2021
Statut:
ppublish
Résumé
To describe the sources of interindividual variability of bevacizumab and trastuzumab pharmacokinetics in early-stage breast cancer, and to study the relationship between exposure and both early clinical response and specific adverse events. Patients (n = 86) received 6 cycles of docetaxel + trastuzumab. Early tumour response was assessed by determination of the maximum standard uptake value (SUV A two-compartment model described the pharmacokinetics of both antibodies satisfactorily. Their central volume of distributions (Vc) increased with body surface area and their elimination half-lives were shorter (~14 days) than previously reported (~26-28 days). There was a time-dependent increase in trastuzumab Vc, positively correlated to baseline SUV Tumour uptake as assessed by SUV
Identifiants
pubmed: 34245336
doi: 10.1007/s00228-021-03179-w
pii: 10.1007/s00228-021-03179-w
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Docetaxel
15H5577CQD
Bevacizumab
2S9ZZM9Q9V
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1861-1873Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403
doi: 10.1016/j.ejca.2012.12.027
Clark GM, McGuire WL (1991) Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51:944–948
pubmed: 1988136
Menard S, Balsari A, Tagliabue E, Camerini T, Casalini P, Bufalino R, Castiglioni F, Carcangiu ML, Gloghini A, Scalone S, Querzoli P, Lunardi M, Molino A, Mandara M, Mottolese M, Marandino F, Venturini M, Bighin C, Cancello G, Montagna E, Perrone F, De Matteis A, Sapino A, Donadio M, Battelli N, Santinelli A, Pavesi L, Lanza A, Zito FA, Labriola A, Aiello RA, Caruso M, Zanconati F, Mustacchi G, Barbareschi M, Frisinghelli M, Russo R, Carrillo G, Group O (2008) Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Ann Oncol 19:1706–1712
doi: 10.1093/annonc/mdn369
Coudert BP, Arnould L, Moreau L, Chollet P, Weber B, Vanlemmens L, Molucon C, Tubiana N, Causeret S, Misset JL, Feutray S, Mery-Mignard D, Garnier J, Fumoleau P (2006) Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 17:409–414
doi: 10.1093/annonc/mdj096
Kurosumi M (2004) Significance of histopathological evaluation in primary therapy for breast cancer–recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer 11:139–147
doi: 10.1007/BF02968293
Alameddine RS, Otrock ZK, Awada A, Shamseddine A (2013) Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges. Curr Opin Oncol 25:313–324
doi: 10.1097/CCO.0b013e32835ff362
Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupre PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo-Riedinger A (2014) Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. Lancet Oncol 15:1493–1502
doi: 10.1016/S1470-2045(14)70475-9
Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P (2005) Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56:361–369
doi: 10.1007/s00280-005-1026-z
Cosson VF, Ng VW, Lehle M, Lum BL (2014) Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemother Pharmacol 73:737–747
doi: 10.1007/s00280-014-2400-5
Bernadou G, Campone M, Merlin JL, Gouilleux-Gruart V, Bachelot T, Lokiec F, Rezai K, Arnedos M, Dieras V, Jimenez M, Paintaud G, Ternant D (2016) Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. Br J Clin Pharmacol 81:941–948
doi: 10.1111/bcp.12875
Quartino AL, Li H, Kirschbrown WP, Mangat R, Wada DR, Garg A, Jin JY, Lum B (2019) Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin((R))), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors. Cancer Chemother Pharmacol 83:329–340
doi: 10.1007/s00280-018-3728-z
Baselga J (2001) Phase I and II clinical trials of trastuzumab. Ann Oncol 12(Suppl 1):S49-55
doi: 10.1093/annonc/12.suppl_1.S49
Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779–786
doi: 10.1007/s00280-007-0664-8
Arjaans M, Oosting SF, Schroder CP, de Vries EG (2013) Bevacizumab-induced vessel normalization hampers tumor uptake of antibodies–response. Cancer Res 73:7147–7148
doi: 10.1158/0008-5472.CAN-13-2532
Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, Cain G, Van Hoy M, Majidy N, Bheddah S, dela Cruz Chuh J, Kozak KR, Lewin-Koh N, Nauka P, Bumbaca D, Sliwkowski M, Tibbitts J, Theil FP, Fielder PJ, Khawli LA, Boswell CA (2012) Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther 11:752–762
doi: 10.1158/1535-7163.MCT-11-0742-T
Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, Hollema H, de Jong JR, de Jong IJ, de Haas S, Scherer SJ, Sluiter WJ, Dierckx RA, Bongaerts AH, Gietema JA, de Vries EG (2015) 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. J Nucl Med 56:63–69
doi: 10.2967/jnumed.114.144840
Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P (1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16:223–228
Ternant D, Ceze N, Lecomte T, Degenne D, Duveau AC, Watier H, Dorval E, Paintaud G (2010) An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics. Ther Drug Monit 32:647–652
doi: 10.1097/FTD.0b013e3181ef582a
Bernadou G CM, Merlin J-L, Gouilleux-Gruart V, Lokiec F, Rezai K, Delaloge S, Diéras V, Jimenez M, Paintaud G, Ternant D (2015) Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. Submitted
Comets E, Brendel K, Mentre F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Prog Biomed 90:154–166
doi: 10.1016/j.cmpb.2007.12.002
Reijers JA, van Donge T, Schepers FM, Burggraaf J, Stevens J (2016) Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies. Eur J Clin Pharmacol 72:1343–1352
doi: 10.1007/s00228-016-2101-6
Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Arends R, Foon KA, Schwab G, Dutcher J (2004) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22:3003–3015
doi: 10.1200/JCO.2004.11.061
Dirks NL, Nolting A, Kovar A, Meibohm B (2008) Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol 48:267–278
doi: 10.1177/0091270007313393
Azzopardi N, Lecomte T, Ternant D, Boisdron-Celle M, Piller F, Morel A, Gouilleux-Gruart V, Vignault-Desvignes C, Watier H, Gamelin E, Paintaud G (2011) Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. Clin Cancer Res 17:6329–6337
doi: 10.1158/1078-0432.CCR-11-1081
Petitcollin A, Bensalem A, Verdier MC, Tron C, Lemaitre F, Paintaud G, Bellissant E, Ternant D (2019) Modelling of the time-varying pharmacokinetics of therapeutic monoclonal antibodies: a literature review. Clin Pharmacokinet
Lioger B, Edupuganti SR, Mulleman D, Passot C, Desvignes C, Bejan-Angoulvant T, Thibault G, Gouilleux-Gruart V, Melet J, Paintaud G, Ternant D (2017) Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. Br J Clin Pharmacol 83:1773–1781
doi: 10.1111/bcp.13270
Thurlings RM, Teng O, Vos K, Gerlag DM, Aarden L, Stapel SO, van Laar JM, Tak PP, Wolbink GJ (2010) Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 69:409–412
doi: 10.1136/ard.2009.109041
Li J, Gupta M, Jin D, Xin Y, Visich J, Allison DE (2013) Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. Cancer Chemother Pharmacol 71:575–580
doi: 10.1007/s00280-012-2031-7
Panoilia E, Schindler E, Samantas E, Aravantinos G, Kalofonos HP, Christodoulou C, Patrinos GP, Friberg LE, Sivolapenko G (2015) A pharmacokinetic binding model for bevacizumab and VEGF in colorectal cancer patients. Cancer Chemother Pharmacol
Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843–850
doi: 10.1200/JCO.2001.19.3.843
Caulet M, Lecomte T, Bouche O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Leger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D (2016) Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Clin Pharmacokinet 55:1381–1394
doi: 10.1007/s40262-016-0406-3
Tout M, Casasnovas O, Meignan M, Lamy T, Morschhauser F, Salles G, Gyan E, Haioun C, Mercier M, Feugier P, Boussetta S, Paintaud G, Ternant D, Cartron G (2017) Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood 129:2616–2623
doi: 10.1182/blood-2016-10-744292
Arjaans M, Munnink THO, Oosting SF, van Scheltinga AGT, Gietema JA, Garbacik ET, Timmer-Bosscha H, Lub-de Hooge MN, Schroder CP, de Vries EG (2013) Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res 73:3347–3355